• XSTEM license deal possible in 2024
• Targinta develops tumour-directed cancer treatments in a hot field
• We initiate coverage with a fair value of
The full report is available here.
© Modular Finance, source
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.248 SEK | -1.20% | -0.40% | -8.49% |
02-28 | Xintela AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 | CI |
02-20 | Xintela Names New Chief Scientific Officer | MT |
• XSTEM license deal possible in 2024
• Targinta develops tumour-directed cancer treatments in a hot field
• We initiate coverage with a fair value of
The full report is available here.
© Modular Finance, source
1st Jan change | Capi. | |
---|---|---|
-8.49% | 13.31M | |
+41.79% | 54.04B | |
+45.77% | 41.96B | |
-0.56% | 41.92B | |
-7.20% | 28.35B | |
+12.59% | 26.35B | |
-21.51% | 19B | |
+6.92% | 13B | |
+29.60% | 12.28B | |
+24.91% | 12.19B |